Mesoblast is developing adult stem cell therapies based on its proprietary mesenchymal precursor stem cell and culture-expanded mesenchymal stem cell technology platforms. It has nine clinical trial programs across four major areas (cardiovascular, spine disease, immunologic/inflammatory, and cancer) targeting chronic diseases affecting large populations.